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Abstract
Background: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish
neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels
of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in
samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a
marker for NPSLE.
Methods: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC)
inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for
each of these patients. For the NP patients we tested samples taken before, during and after the NP event.
Results: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these
patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were
not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P= 0.006). The predominant
clinical features in this group of 190 patients were headache, mood disorders and anxiety.
Conclusions: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are
needed to determine the value of serum NN as a biomarker for NPSLE.
Keywords: Systemic lupus erythematosus, Neuropsychiatric, Nucleosomes, Nitration
* Correspondence: anisur.rahman@ucl.ac.uk
1Centre for Rheumatology Research, University College London, Fourth Floor
Rayne Institute, 5 University Street, London WC1E 6JF, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ferreira et al. Arthritis Research & Therapy  (2017) 19:287 
DOI 10.1186/s13075-017-1495-6
Background
Neuropsychiatric manifestations of systemic lupus
erythematosus (NPSLE) can take many different forms as
defined by the American College of Rheumatology (ACR)
case definitions in 1999 [1]. A study from the Systemic
Lupus International Collaborative Clinics (SLICC)
inception cohort in 2011 showed that 40% of 1206 newly
diagnosed patients with SLE followed for a mean of
1.9 years developed at least one NP event [2]. Those with
NP events had reduced quality of life, but the majority of
these events were not attributed to SLE.
The NP events in the SLICC study were defined as either
attributable to SLE or not attributable to SLE according to
pre-determined classification rules [2]. For example, all
isolated headaches (not occurring in association with
another NPSLE event) were classified as not being attribut-
able to SLE. Only a minority (30%) of the 843 NP events
analysed were attributed to SLE, but these events were
more likely to resolve than those not due to SLE [2]. This
observation underlines the importance of developing
biomarkers to identify those NP events that are caused by
SLE. Currently there are no serological or imaging markers
that will do this accurately, though an association between
antiphospholipid antibodies and cerebrovascular events
has been reported [3]. Potential biomarkers for NPSLE that
have previously been studied are autoantibodies, cytokines
or chemokines (reviewed in [4]). Despite a large number of
studies over the last 30 years none of these biomarkers has
shown a robust association with either NPSLE in general
or with any specific NPSLE manifestation [4]. Similarly, a
multi-centre report of neuroimaging appearances in 112
patients with NPSLE [5] identified no specific findings on
magnetic resonance imaging (MRI) that clearly characterise
NPSLE. The most common appearance was of non-specific
vascular abnormalities.
In a recent paper we used a novel capture enzyme-linked
immunosorbent assay (ELISA) to measure levels of nitrated
nucleosomes (NN) in patients with SLE. Nucleosomes are
released from apoptotic cells and the removal of this apop-
totic debris is retarded in patients with SLE [6]. Both
nucleosome level and anti-nucleosome antibodies are ele-
vated in patients with SLE [7] and the latter are associated
with disease activity, especially lupus nephritis [8]. Williams
et al. used a monoclonal murine anti-nucleosome antibody
4H7 to assay serum nucleosome levels in 140 patients with
SLE. They showed that nucleosome levels are strongly
associated with disease activity measured by the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI)
score and were particularly high in patients with active
nephritis or NPSLE [9]. Deposits of extracellular chromatin
are found in renal biopsies from patients with lupus
nephritis [10].
Nitric oxide (NO) produced by the endothelium [11]
can cause irreversible nitration of tyrosine residues
within proteins. Levels of serum NO are elevated in
patients with SLE [11] and nitrotyrosine levels are higher
in patients with active lupus nephritis than in those
without nephritis [12].
Thus, since both nitration and nucleosome levels are
associated with active SLE, our hypothesis was that
levels of NN could be a marker of disease activity in
patients with SLE. We measured serum NN in 397
samples taken longitudinally from 49 patients (mean 8
samples per patient) with SLE at times of different
disease activity [13]. Serum NN levels were significantly
higher in patients with SLE than in healthy control
subjects or patients with other autoimmune rheumatic
diseases [13]. However, only a subgroup (n = 31) of the
patients with SLE had detectable serum NN at any time
point. In those 31 patients, serum NN did vary over time
but not in parallel with disease activity. Patients with
NPSLE flares (defined as scoring A or B in the
neuropsychiatric domain of the British Isles Lupus
Assessment Group (BILAG) index) had mean NN twice
the level in those without NP flares. However, this differ-
ence was based on only 18 samples from 11 patients and
was not statistically significant [13].
To extend this research, we obtained serum samples
from patients in the large SLICC inception cohort with
documented NP events, and control samples from
patients in the cohort without NP events. We tested
serum NN in all patients, including longitudinal samples
taken before, during and after the NP event. The objective
was to determine if a transient rise in serum NN occurred
concurrently with an NP event.
Methods
All samples were obtained from patients enrolled in the
SLICC inception cohort. This cohort has been described
in previous papers [2, 3, 14]. Briefly, it comprises over
1600 patients recruited within 15 months of being diag-
nosed with SLE, from 31 centres across North America,
Europe and Asia. All patients gave informed consent
and ethical approval for the study was obtained by the
institutional research ethics review board at each partici-
pating centre. Clinical data and blood samples from
these patients were collected annually and submitted to
the study centres in Toronto and Halifax, Canada.
Neuropsychiatric (NP) events
An enrolment window extended from 6 months prior to
the diagnosis of SLE up to the actual enrolment date.
NP events were characterized within this window using
the ACR case definitions for 19 NP syndromes [1].
These events were diagnosed by clinical evaluation sup-
ported by investigations, if clinically warranted, as per
the ACR guidelines. Patients were reviewed annually
within a 6-month window around the anniversary of
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enrolment. New NP events (since the last study visit)
and the status of previous NP events since the last study
visit were determined at each assessment.
Attribution of NP events
In keeping with other publications on NP events within
the SLICC NPSLE inception cohort, the same decision
rules were used to determine the attribution of all NP
events [2, 15]. To optimize consistency this determin-
ation was performed at the central coordinating centre
in Halifax using data provided in the case record form
by individual SLICC sites. Factors considered in the
decision rules included: (i) the time of onset of NP
event(s) in relation to the diagnosis of SLE; (ii) concur-
rent non-SLE factor(s), identified from the ACR glossary,
which accompanied the case definitions of NP events [1]
as potential causes (“exclusions”) or contributing factors
(“associations”) for each NP syndrome and (iii) “common”
NP events that are frequent in normal population controls
as described by Ainiala et al. [16]. These included all
isolated headaches, mild depression (mood disorders
failing to meet criteria for “major depressive-like
episodes”), anxiety, mild cognitive impairment (deficits in
fewer than three of the eight specified cognitive domains)
and polyneuropathy without electrophysiological confirm-
ation. Two attribution decision rules of different strin-
gency (models A and B) were developed as described in
detail elsewhere [2, 15]. NP events that fulfilled criteria for
model A (most stringent) or for model B (least stringent)
were attributed to SLE. By definition, all NP events attrib-
uted to SLE using model A were included in the group of
NP events using model B. Those events that did not fulfil
these criteria were attributed to non-SLE causes (non-A,
non-B events). Non-A, non-B events comprised 70% of all
events [2].
We tested samples from 26 patients with model-A NP
events and 190 with non-A, non-B events (i.e. 216
patients with NP events in total). For each of these pa-
tients we attempted to obtain and test three samples;
one from the date closest to the event, one from before
that date and one from after. These were defined as the
onset, pre-event and post-event samples, respectively.
For each of the 216 patients with NP events we tested
samples from two age-matched and sex-matched con-
trols from the inception cohort who had no recorded
NP events. Only one sample from each control subject
was tested. We also tested samples from 16 patients with
a history of chronic migraine who did not have SLE or
any other autoimmune rheumatic disease. These patients
were recruited with informed consent from the Head-
ache Clinic at the National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK. In our previ-
ous paper [13] we showed that none of 37 healthy
controls had any detectable serum NN, so we did not
repeat testing of healthy controls in this study.
Assay for measuring nitrated nucleosomes
The whole assay was done at room temperature (RT)
except where specified and plates were washed three to
four times with PBS-0.1% Tween (PBST) between steps:
96-well streptavidin plates were divided in half and the
test side was coated with biotinylated polyclonal goat
anti-nitrotyrosine antibody (Abcam 27646) diluted
1:1000 in PBS, and the control side coated with PBS
(75 μL per well). After one hour incubation plates were
washed and blocked with 200 μL of 0.5% ovalbumin in
PBST (OVA-BST) for one hour. After washing, serum
samples were loaded in duplicate onto the plates
(100 μL/well) at 1:30 dilution in PBS, such that each
sample was loaded in two wells on the test side and two
matching wells on the control side. After one hour incu-
bation at 37 °C and washing, 50 μL per well of rabbit anti-
histone H3 antibody (sc-10809, Santa Cruz Biotechnology)
diluted at 1:2000 in OVA-BST was added and the plates
were incubated for one hour. After washing, 50 μL per
well of goat anti-rabbit IgG horse radish peroxidase (HRP)
conjugate (Dako P0448) diluted at 1:2000 in 0.5%
OVA-BST was added. After incubating for one hour and
washing, HRP substrate was added (100 μL per well) and
incubated for 10 min. The reaction was stopped with
100 μL sulphuric acid and optical density (OD) read at
450 nm. The net optical density (OD) reading for each
sample was calculated by subtracting the OD in the
control well from that in the matching test well to exclude
non-specific background binding.
In order to be able to compare OD values obtained
from different plates on different days we prepared an
in-house standard positive control sample that was
loaded in serial dilutions (range 1:15–1:120) on every
plate. This in-house standard was prepared by pooling
serum samples from several patients who had been
found to have high serum NN levels in this assay. The
mean net OD from duplicate test samples was converted
to absorbance units (AU) by comparison to the standard
curve of OD for the serial dilutions of the positive
control sample on each plate; 100 AU was defined as the
OD given by a 1:30 dilution of the positive control
sample. The OD for this sample was reproducibly high,
ranging between 1.03 and 1.37. This assay was reprodu-
cible with an intra-plate and inter-plate coefficient of
variation of < 10%.
Statistical analysis
All statistical analysis was done using Prism Graphpad
6.0® (GraphPad Software Inc, La Jolla, CA 92037 USA).
The main outcome measure was serum NN, which did
not follow a normal distribution (Shapiro-Wilk normality
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test). The highly positive skewed distribution could not be
transformed to a normally distributed scale, thus the
outcomes were assumed to follow a negative binomial
distribution and non-parametric tests were selected.
Variables measured at the patient level were compared
between groups using either Fisher’s exact test for the
categorical variables or the unpaired t test for continuous
variables. Continuous variables with a positively skewed
distribution were log-transformed before the analysis.
Results
Table 1 shows the demographic and medication data for
each of the subject groups. Table 2 shows the type of NP
event in the model A and the non-A, non-B NP event
groups. As would be expected from the SLICC attribution
rules, the groups are very different. In the non-A, non-B
group 185/190 events were headache, anxiety disorder or
mood disorder, whereas these three manifestations
accounted for only one case in the model-A group.
Considering all 216 patients who had events, the median
time between the date of the NP event and the date of the
onset sample was 2 months (maximum 6 months). Of the
onset samples, 67 came from a time point before the event
and 149 from after the event.
Patients with model-A NP events
Figure 1 shows that there were no significant differences
between median serum NN in the pre-event, onset and
post-event samples or matched controls (P = 0.46, one-way
analysis of variance (ANOVA)).
Patients with non-A, non-B NP events
Figure 2 shows that median serum NN was highest in
the onset sample compared to pre-event or post-event
samples (P = 0.006, one-way ANOVA). Mean serum NN
for onset samples was also significantly higher than in
the matched controls (P < 0.001, Wilcoxon test).
Figure 3 shows the pattern of serum NN levels over
time in all 190 patients with non-A, non-B NP events,
illustrating the rise at the time of the onset sample,
followed by a fall, in some patients.
Since headache was the dominant clinical feature in
the non-A, non-B group (157/190 patients (83%)), we
investigated whether rise in serum NN is a non-specific
effect associated with headache in general. We tested
samples from 16 patients with chronic migraine who
had no known autoimmune rheumatic disease (mean
age 48.3 years, 15 white, 9/16 female). None of these
patients had any detectable serum NN. In our previous
paper we found no detectable serum NN in 37 healthy
controls and 11/13 patients with rheumatoid arthritis,
11/12 with myositis and 9/13 with Sjogrens’ syndrome,
so overall it seems unlikely that a rise in serum NN
occurs commonly as a non-specific event outside the
context of SLE [13].
We also tested for any association between serum NN
and the following measures of disease activity; C3, anti-
dsDNA, global SLEDAI score, SLEDAI score excluding
serology (anti-DNA and complement), renal SLEDAI and
SLEDAI excluding NP variables. There was no association
between serum NN and any of these variables in either
group of patients with NP events (model A or non-A,
non-B) or the matched controls. When the analysis was
restricted only to patients with headaches or only to
patients with serum NN above the 90th percentile of
healthy controls there were still no associations.
Discussion
Apart from the recognised association between
antiphospholipid antibodies and cerebrovascular disease
[3], biomarkers previously thought to show great promise
in the management of NPSLE, such as anti-ribosomal P
antibodies [17] and anti N-methyl-D-aspartate receptor
antibodies [18], have not come into widespread clinical
Table 1 Demographic and treatment characteristics of patients with SLE studied at the time of the onset sample
Model-A NP
event
Matched controls for
model-A NP events
Non-A, non-B NP events Matched controls for non-A, non-B
NP events
Number of subjects 26 52 190 380
Mean (SD) age 34.4 (7.5) 36.9 (10.9) 33.3 (11.8) 35.3 (11.5)
Gender (female:male) 21:5 42:10 177:13 353:27
Ethnicity 9 W, 6 A-C, 4 SA, 4
EA, 3 H
22 W, 12 A-C, 4 SA, 7 EA,
6 H, 1 other
84 W, 30 A-C, 4 SA, 41 EA,
18 H, 13 other
161 W, 61 A-C, 13 SA, 81 EA, 36 H, 26
other, 2 unknown
Median dose of
corticosteroids (mg)
10 0.25 7.5 5
Number (%) taking
anti-malarials
16 (61) 22 (42) 140 (74) 222 (58)
Number (%) taking
immunosuppressant drugs
13 (50) 10 (19) 71 (37) 144 (38)
Demographic and clinical characteristics of the patients with systemic lupus erythematosus (SLE) studied in all four groups. NP neuropsychiatric, W white, A-C
Afro-Caribbean, EA East Asian, SA South Asian, H Hispanic
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Table 2 Type of NP event in patients with model A compared to non-A, non-B events
Type of NP event Number of events in model-A group
(total n = 26)
Number of events in non-A, non-B group (total n = 190)
Acute inflammatory demyelinating polyneuropathy 1 0
Aseptic meningitis 1 1
Cerebrovascular disease 2 0
Headache 0 157
Mononeuropathy 3 1
Cranial neuropathy 4 0
Polyneuropathy 1 0
Seizures 7 2
Acute confusional state 1 1
Anxiety disorder 0 10
Cognitive dysfunction 1 0
Mood disorders 1 18
Psychosis 4 0
The table shows the nature of the neuropsychiatric (NP) events comparing patients in the model-A and non-A, non-B groups
Fig. 1 Serum nitrated nucleosomes (NN) levels in pre-event, onset and post-model-A event samples compared to matched controls (MC). Pre-event
samples were available for 12 patients, onset samples for 24 patients and post-event samples for 25 patients. AU absorbance units
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use. It is difficult to validate any putative biomarker in
NPSLE because it is a rare condition and because many
patients with SLE have NP events not caused by the dis-
ease itself [2]. Our previous study had raised the possibil-
ity that elevated serum NN could be a marker of NPSLE,
but was limited by small numbers of patients and a limited
variety of NP events. In order to address these limitations,
we accessed samples and clinical data from the SLICC in-
ception cohort, which is one of the largest populations in
which comprehensive data on NPSLE events are available.
Even in this multi-national cohort of over 1600 patients,
we were only able to study 26 patients with model-A NP
events and for half of these 26 patients we did not have a
full set of pre-event, onset and post-event samples. We
could not show any relationship between elevated serum
NN and NP events in these 26 patients.
Our original purpose in including patients with NP
events not attributed to SLE was as a control group in
which we did not expect to see a rising and falling
pattern of serum NN. However, in the event, the serum
NN level was statistically higher at event onset in this
group than in the pre-event or post-event samples or in
the matched controls. We did not detect any similar
statistically significant result in patients with model-A
NP events, perhaps due to the much smaller numbers in
that group.
We considered a number of possible explanations for
these serum NN results in patients with non-A, non-B
events. The highly significant P values suggest that this
was not a random or chance finding. These were not
simply individuals with constitutively high levels of
serum nitration, as the pre-event samples had very low
serum NN levels. Since the majority of the events were
headaches it was possible that elevated serum NN is a
non-specific effect of headache, but this seems unlikely
because we found no NN in serum from any patients
who suffer chronic headache but do not have lupus. It
was also possible that the rise in serum NN could have
been due to lupus activity in non-NP systems but we
found no association between serum NN and any
marker of global, serological or organ-specific disease
activity that was assessed in this paper (in any of the
patient groups). Nor did we find such associations in
our previous paper [13].
Under conditions of systemic inflammation, excess
nitric oxide (NO) produced by the vascular endothelium
[11] can cause irreversible nitration of tyrosine residues
on serum proteins including histones in nucleosomes.
NO is also believed to contribute to the causation of
headaches through its effects on cerebral and extra-
cerebral cranial blood flow [19]. In patients with SLE,
serum nitrite plus nitrate level (an index for NO
production) correlates with disease activity and levels of
anti-dsDNA antibodies [11, 12]. There are also potential
links between nitration and NPSLE. Human astrocytes
are known to express inducible nitric oxide synthase
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Fig. 2 Serum nitrated nucleosomes (NN) levels in pre-event, onset and post-non-A, non-B event samples compared to matched controls (MC).
Pre-event samples were available for 106 patients, onset samples for 182 patients and post-event samples for 181 patients. AU absorbance units
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(iNOS) which can be stimulated by cytokines including
interleukin-1β and interferon gamma [20]. A Swedish
group showed in 1998 that total cerebrospinal fluid
(CSF) (nitrite + nitrate) was higher in patients with
NPSLE than in age-matched and sex-matched controls
and higher in patients with severe compared to those
with mild NPSLE [21]. In a subsequent study of 30
patients who had NPSLE (with clinical features fulfilling
the ACR case definitions [1]), the same group confirmed
significantly higher CSF (nitrate + nitrite) in 7 patients
with severe NPSLE (psychosis, dementia, combinations
of several NP manifestations) compared to 23 patients
with mild or moderate NPSLE (including cognitive
impairment, seizures, headache, anxiety, mood
disorders) [22].
The concept of lupus headache is complex and many
papers have suggested that it is of limited usefulness be-
cause headache is such a common complaint (in people
with or without SLE). For example, in a meta-analysis,
Mitsikostas et al. showed that although headache occurs
in 50% of patients with SLE, this is not significantly dif-
ferent from the population prevalence of this very com-
mon symptom [23]. Furthermore there was no clear
evidence that headache in patients with SLE was related
to disease activity or arose from a specific autoimmune
or inflammatory mechanism [23]. Analysis of headaches
in the SLICC inception cohort showed a prevalence of
17.8% at enrolment and that 58% of subjects suffered
headache at some time over a 10-year follow-up period
[14]. Only 27 of 697 headaches were identified as lupus
headaches by the treating physician. However, there was
no consensus on the characteristics of headache in this
group as reflected by the headache subtypes in the case
definitions. Of these 27 lupus headaches, 26 resolved
over a mean follow-up period of 3.8 years [14].
There are a number of limitations affecting our analysis.
As noted previously, we did not have a full complement of
samples for most of the patients with model-A events.
Since clinical data and blood samples are obtained annu-
ally for the SLICC study, the time period between the pre-
event, onset and post-event samples ranged from a few
months to several years. However, the onset samples were
from time points close to the event (median gap 2 months,
maximum 6 months). In our previous smaller study in 49
patients, higher serum NN was seen in patients on
hydroxychloroquine or immunosuppressant drugs. In the
current study, the patients with model-A NP events were
on higher corticosteroid doses and were more likely to be
taking immunosuppressant drugs than the matched con-
trols (Table 1), but there were no corresponding
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Fig. 3 Changes in serum nitrated nucleosomes (NN) levels of patients with non-A, non-B neuropsychiatric events over time. AU absorbance units
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differences between the patients with non-A, non-B
events and their controls. We considered obtaining
further samples from patients who had NP events that
were due to SLE under model B but not model A.
However, the study centre in Toronto informed us that
there were only eight such subjects for whom sufficient
samples were available and this was not pursued.
Although we have used the term nitrated nucleosomes
in this paper, we stressed in our previous paper and repeat
here that our assay could potentially detect any analyte
that contains both histones and nitrotyrosine, for example
nucleosome fragments or nitrated free histones. However,
published evidence shows that circulating free histones
are rarely found except in conditions such as severe
trauma [24]. Specifically, although the presence of
circulating nucleosomes in blood has been established for
many years [7, 25], sub-nucleosome components are
rapidly cleared through the liver and thus are rarely
detectable [26]. In fact circulating histones are toxic to
endothelial cells [24]. It is important to be clear, however,
that this assay has not been validated using purified
nucleosomes and this validation would be an important
step before it could be used in clinical practice.
Use of the serum NN assay clinically cannot yet be
advocated based on these results alone. Though the capture
ELISA is reproducible in our hands, with inter-plate and
intra-plate variation < 10%, it has not yet been carried out
elsewhere and the standard positive control used to
quantify the results is a blend of serum from our patients..
Conclusions
In previous studies both nitration and nucleosomes have
been found to be elevated in association with active SLE.
In this multi-centre study we found that serum NN
levels rise at the time of an NP event in a proportion of
patients with SLE, including some cases of headache.
Further studies are needed to determine the value of
serum NN as a biomarker for NPSLE. The NN assay will
require further validation and standardisation of the
nature and biochemistry of the antigen being recognised.
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